-
1.发明授权N-ureidoalkyl-amino compounds as modulators of chemokine receptor activity 有权N-脲基烷基 - 氨基化合物作为趋化因子受体活性的调节剂公开(公告)号：US07291744B2
公开(公告)日：2007-11-06
申请号：US10987808
申请日：2004-11-12
申请人： Soo S. Ko , Douglas G. Batt , George V. Delucca , John V. Duncia , Daniel S. Gardner , Joseph B. Santella
发明人： Soo S. Ko , Douglas G. Batt , George V. Delucca , John V. Duncia , Daniel S. Gardner , Joseph B. Santella
IPC分类号： C07D239/02 , C07D285/08 , C07D277/22 , C07D277/24 , C07D257/04 , C07D231/56 , C07D317/44
CPC分类号： A61K31/506 , A61K31/454 , A61K31/497 , A61K31/501 , C07C275/30 , C07C275/34 , C07C275/38 , C07C2601/02 , C07C2601/14 , C07D231/56 , C07D239/26 , C07D257/04 , C07D277/48 , C07D285/135 , C07D317/64 , C07D317/66 , C07D401/12 , C07D403/12
摘要： The present application describes modulators of chemokine receptors of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma and other allergic diseases.
摘要翻译： 本申请描述了可用于预防哮喘和其它过敏性疾病的式（I）的趋化因子受体的调节剂：或其药学上可接受的盐形式。
-
公开(公告)号：US07183270B2
公开(公告)日：2007-02-27
申请号：US10776828
申请日：2004-02-11
IPC分类号： A61K31/397 , A61K31/5383 , A61K31/496 , A61K31/454 , A61K61/4015 , C07D413/12 , C07D403/12 , C07D401/12 , C07D207/77 , C07D207/00 , C07D205/04
CPC分类号： C07D207/273 , C07D207/277 , C07D207/34 , C07D207/416 , C07D211/76 , C07D211/88 , C07D223/12 , C07D401/12 , C07D403/04 , C07D403/12 , C07D405/06 , C07D409/12 , C07D417/08 , C07D417/12 , C07D471/04 , C07D487/04 , C07D495/04
摘要： The present application describes modulators of MCP-1 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of rheumatoid arthritis, multiple sclerosis, atherosclerosis and asthma, processes for preparing and intermediates thereof.
-
3.发明授权公开(公告)号：US07985861B2
公开(公告)日：2011-07-26
申请号：US12505724
申请日：2009-07-20
申请人： Percy H. Carter , Cullen L. Cavallaro , John V. Duncia , Daniel S. Gardner , John Hynes , Rui-Qin Liu , Joseph B. Santella , Dharmpal S. Dodd
发明人： Percy H. Carter , Cullen L. Cavallaro , John V. Duncia , Daniel S. Gardner , John Hynes , Rui-Qin Liu , Joseph B. Santella , Dharmpal S. Dodd
IPC分类号： C07D211/06 , A61K31/535
CPC分类号： C07D211/52 , C07D211/18 , C07D211/38 , C07D211/58 , C07D211/70 , C07D401/12 , C07D401/14 , C07D405/12 , C07D409/12 , C07D413/12 , C07D417/12 , C07D417/14 , C07D471/04 , C07D487/04 , C07D491/10 , C07D491/107
摘要： The present application describes substituted piperidinyl modulators of MIP-1α or CCR-1 or stereoisomers or pharmaceutically acceptable salts thereof. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and transplant rejection using said modulators are disclosed.
摘要翻译： 本申请描述了MIP-1α或CCR-1的取代的哌啶基调节剂或其立体异构体或其药学上可接受的盐。 此外，公开了使用所述调节剂治疗和预防炎症性疾病如哮喘和过敏性疾病以及自身免疫性病症如类风湿性关节炎和移植排斥的方法。
-
公开(公告)号：US20120149733A1
公开(公告)日：2012-06-14
申请号：US13160944
申请日：2011-06-15
IPC分类号： A61K31/451 , A61P19/02 , A61P7/00 , A61P29/00 , A61P9/00 , A61P1/00 , A61P9/04 , A61P37/00 , A61P31/18 , A61P25/28 , A61P17/06 , A61P9/10 , A61P25/00 , A61P1/04 , A61P19/04 , A61P1/16 , A61P11/06 , A61P37/06 , A61P35/00 , C07D211/52
CPC分类号： C07D211/52 , A61K31/451
摘要： The present application describes the compound of formula (I): or stereoisomers or pharmaceutically acceptable salts thereof. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and arthrosclerosis using the compound of the invention are disclosed.
摘要翻译： 本申请描述了式（I）化合物或其立体异构体或其药学上可接受的盐。 此外，公开了使用本发明的化合物治疗和预防炎症性疾病如哮喘和过敏性疾病以及自身免疫病态如类风湿性关节炎和关节病的方法。
-
公开(公告)号：US20100204274A1
公开(公告)日：2010-08-12
申请号：US12670016
申请日：2008-07-23
申请人： Daniel S. Gardner , John V. Duncia , John Hynes , T.G. Murali Dhar , Percy H. Carter , Joseph B. Santella
发明人： Daniel S. Gardner , John V. Duncia , John Hynes , T.G. Murali Dhar , Percy H. Carter , Joseph B. Santella
IPC分类号： A61K31/4545 , C07D401/12 , A61K31/454 , C07D211/94 , A61K31/451 , C07D405/06 , C07D213/89 , A61P19/00 , A61P29/00 , A61P37/00
CPC分类号： C07D401/12 , C07D211/52 , C07D405/12
摘要： The present application describes modulators of MIP-1α of formula (I) or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein m, Q, T, W, Z, R1, R3, R4, R5, R5a and R5b, are as defined herein. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis using the modulators of formula (I) are disclosed.
摘要翻译： 本申请描述了式（I）的MIP-1α或其立体异构体或前药或其药学上可接受的盐的调节剂，其中m，Q，T，W，Z，R 1，R 3，R 4，R 5，R 5a和R 5b如上定义 这里。 此外，公开了使用式（I）的调节剂治疗和预防炎性疾病如哮喘和过敏性疾病以及类风湿性关节炎和动脉粥样硬化的自身免疫病态的方法。
-
公开(公告)号：US20070208056A1
公开(公告)日：2007-09-06
申请号：US11625874
申请日：2007-01-23
申请人： Percy H. Carter , Cullen L. Cavallaro , John V. Duncia , Daniel S. Gardner , John Hynes , Rui-Qin Liu , Joseph B. Santella , Dharmpal S. Dodd
发明人： Percy H. Carter , Cullen L. Cavallaro , John V. Duncia , Daniel S. Gardner , John Hynes , Rui-Qin Liu , Joseph B. Santella , Dharmpal S. Dodd
IPC分类号： A61K31/454 , A61K31/445 , C07D211/22 , C07D401/02
CPC分类号： C07D211/52 , C07D211/18 , C07D211/38 , C07D211/58 , C07D211/70 , C07D401/12 , C07D401/14 , C07D405/12 , C07D409/12 , C07D413/12 , C07D417/12 , C07D417/14 , C07D471/04 , C07D487/04 , C07D491/10 , C07D491/107
摘要： The present application describes substituted piperidinyl modulators of MIP-1α or CCR-1 or stereoisomers or pharmaceutically acceptable salts thereof. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and transplant rejection using said modulators are disclosed.
摘要翻译： 本申请描述了MIP-1α或CCR-1的取代的哌啶基调节剂或其立体异构体或其药学上可接受的盐。 此外，公开了使用所述调节剂治疗和预防炎症性疾病如哮喘和过敏性疾病以及自身免疫性病症如类风湿性关节炎和移植排斥的方法。
-
7.发明申请公开(公告)号：US20110245226A1
公开(公告)日：2011-10-06
申请号：US13155460
申请日：2011-06-08
申请人： Percy H. Carter , Cullen L. Cavallaro , John V. Duncia , Daniel S. Gardner , John Hynes , Rui-Qin Liu , Joseph B. Santella , Dharmpal S. Dodd
发明人： Percy H. Carter , Cullen L. Cavallaro , John V. Duncia , Daniel S. Gardner , John Hynes , Rui-Qin Liu , Joseph B. Santella , Dharmpal S. Dodd
IPC分类号： A61K31/451 , C07D295/192 , C07D417/12 , C07D409/12 , C07D405/12 , C07D401/12 , C07D403/12 , C07D417/14 , A61K31/454 , A61K31/4535 , A61K31/4525 , A61K31/4545 , A61K31/4709 , A61K31/497 , A61K31/496 , A61K31/5377 , A61K31/4523 , A61P19/02 , A61P9/00 , A61P9/04 , A61P17/06 , A61P31/18 , A61P9/10 , A61P35/00 , A61P19/10
CPC分类号： C07D211/52 , C07D211/18 , C07D211/38 , C07D211/58 , C07D211/70 , C07D401/12 , C07D401/14 , C07D405/12 , C07D409/12 , C07D413/12 , C07D417/12 , C07D417/14 , C07D471/04 , C07D487/04 , C07D491/10 , C07D491/107
摘要： The present application describes substituted piperidinyl modulators of MIP-1α or CCR-1 or stereoisomers or pharmaceutically acceptable salts thereof. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and transplant rejection using said modulators are disclosed.
摘要翻译： 本申请描述了MIP-1α或CCR-1的取代的哌啶基调节剂或其立体异构体或其药学上可接受的盐。 此外，公开了使用所述调节剂治疗和预防炎症性疾病如哮喘和过敏性疾病以及自身免疫性病症如类风湿性关节炎和移植排斥的方法。
-
8.发明授权公开(公告)号：US07601844B2
公开(公告)日：2009-10-13
申请号：US11625874
申请日：2007-01-23
申请人： Percy H. Carter , Cullen L. Cavallaro , John V. Duncia , Daniel S. Gardner , John Hynes , Rui-Qin Liu , Joseph B. Santella , Dharmpal S. Dodd
发明人： Percy H. Carter , Cullen L. Cavallaro , John V. Duncia , Daniel S. Gardner , John Hynes , Rui-Qin Liu , Joseph B. Santella , Dharmpal S. Dodd
IPC分类号： C07D211/60 , A61K31/445
CPC分类号： C07D211/52 , C07D211/18 , C07D211/38 , C07D211/58 , C07D211/70 , C07D401/12 , C07D401/14 , C07D405/12 , C07D409/12 , C07D413/12 , C07D417/12 , C07D417/14 , C07D471/04 , C07D487/04 , C07D491/10 , C07D491/107
摘要： The present application describes substituted piperidinyl modulators of MIP-1α or CCR-1 or stereoisomers or pharmaceutically acceptable salts thereof. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and transplant rejection using said modulators are disclosed.
摘要翻译： 本申请描述了MIP-1α或CCR-1的取代的哌啶基调节剂或其立体异构体或其药学上可接受的盐。 此外，公开了使用所述调节剂治疗和预防炎症性疾病如哮喘和过敏性疾病以及自身免疫性病症如类风湿性关节炎和移植排斥的方法。
-
公开(公告)号：US07338947B2
公开(公告)日：2008-03-04
申请号：US11545584
申请日：2006-10-10
IPC分类号： A61K31/397 , A61K31/5383 , A61K31/496 , A61K31/454 , A61K31/4015 , C07D413/12 , C07D403/12 , C07D401/12 , C07D207/00 , C07D205/04
CPC分类号： C07D207/273 , C07D207/277 , C07D207/34 , C07D207/416 , C07D211/76 , C07D211/88 , C07D223/12 , C07D401/12 , C07D403/04 , C07D403/12 , C07D405/06 , C07D409/12 , C07D417/08 , C07D417/12 , C07D471/04 , C07D487/04 , C07D495/04
摘要： The present application describes modulators of MCP-1 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of rheumatoid arthritis, multiple sclerosis, atherosclerosis and asthma, processes for preparing and intermediates thereof.
摘要翻译： 本申请描述了可用于预防类风湿性关节炎，多发性硬化，动脉粥样硬化和哮喘的式（I）的MCP-1或其药学上可接受的盐形式的调节剂，其制备方法及其中间体。
-
10.发明授权N-ureidoalkyl-piperidines as modulators of chemokine receptor activity 有权作为趋化因子受体活性的调节剂的N-脲基烷基 - 哌啶公开(公告)号：US06992091B2
公开(公告)日：2006-01-31
申请号：US10660347
申请日：2003-09-11
IPC分类号： A61K31/445 , C07D401/04
CPC分类号： C07D401/12
摘要： The present application describes N-ureidoalkyl piperidines as modulators of chemokine receptors, or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma and other allergic diseases.
摘要翻译： 本申请描述了N-脲基烷基哌啶作为趋化因子受体或其药学上可接受的盐形式的调节剂，其可用于预防哮喘和其它过敏性疾病。
-
-
-
-
-
-
-
-
-
搜索结果
21 条记录 (耗时 0.055 秒)
